SEC Form POS AM filed by bioAffinity Technologies Inc.
$BIAF
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
bioAffinity Technologies' noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient's lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation. "We believe that this patient's experience demonstrates the high added value that CyPath® Lung brings to the diagnostic pathway. Multiple procedures and diagnostic tools were incon
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian
One third of world's smokers live in China, which has highest rate of lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to th
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi
SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)